Ozempic and Alcohol Cravings: What the Trials Actually Show

Quick answer: Two randomized trials have now tested semaglutide — the drug in Ozempic and Wegovy — against placebo in people with alcohol use disorder. Both found reductions in drinking and craving. The 2026 Lancet trial reported a 13.7 percentage-point advantage over placebo on heavy drinking days across 26 weeks. The evidence is real and it is early: semaglutide is not approved by the FDA for alcohol use disorder, and every decision about it belongs with a prescriber.

For a couple of years the only evidence about Ozempic and drinking was anecdotal. People taking a GLP-1 drug for diabetes or weight kept saying the same odd thing: the wine stopped calling. Not that they resisted it — that they stopped wanting it.

Anecdotes are where research starts, not where it ends. The useful question is what happened when researchers ran the controlled experiments, and that question now has answers from two randomized trials, a body of animal work, and a pooled review. Here is what each one actually measured, stated at the strength the papers support and no stronger.

What the 2025 Trial Found About Ozempic Alcohol Cravings

The first randomized test of semaglutide in people with alcohol use disorder was published in JAMA Psychiatry in April 2025 by Hendershot and colleagues.

It was a phase 2, double-blind, randomized trial with 9 weeks of outpatient treatment at a single US academic medical center, running from September 2022 to February 2024. Forty-eight adults with alcohol use disorder were randomized — notably, people who were not seeking treatment for their drinking. Doses were low: 0.25 mg weekly for four weeks, 0.5 mg weekly for four weeks, then a single 1.0 mg dose.

The primary outcome was a laboratory drinking session, where participants could drink under observation. Semaglutide reduced grams of alcohol consumed (β = −0.48; 95% CI, −0.85 to −0.11; P = .01) and peak breath alcohol concentration (β = −0.46; 95% CI, −0.87 to −0.06; P = .03).

The secondary outcomes are where the honesty lives. There was no significant effect on average drinks per calendar day or on the number of drinking days. What did move was intensity and wanting: drinks per drinking day (β = −0.41; 95% CI, −0.73 to −0.09; P = .04) and weekly alcohol craving (β = −0.39; 95% CI, −0.73 to −0.06; P = .01). In the subsample who smoked, cigarettes per day fell too.

The authors' own conclusion is the right summary: the findings provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials. Forty-eight people over nine weeks is a signal, not a verdict.

What the 2026 Trial Added

The larger, longer test arrived in The Lancet in May 2026, from Klausen and colleagues in Denmark.

This one enrolled 108 participants with alcohol use disorder and comorbid obesity, 54 per group, and ran for 26 weeks. Everyone — both arms — received cognitive behavioral therapy, so the trial tested semaglutide added to therapy rather than instead of it. The dose was the full 2.4 mg weekly, against saline placebo. Eighty-eight participants (81%) completed the intervention.

On the primary outcome, heavy drinking days, both groups improved substantially. The semaglutide group fell 41.1 percentage points from baseline (95% CI, −48.7 to −33.5); the placebo group fell 26.4 points (95% CI, −34.1 to −18.6). The estimated treatment difference was −13.7 percentage points (95% CI, −22.0 to −5.4; p=0.0015).

Read those numbers together and two things stand out. Semaglutide beat placebo, clearly. And placebo-plus-therapy produced a 26-point drop on its own — a reminder that showing up, being measured weekly, and doing CBT moves the needle by a lot before any drug is involved.

Secondary outcomes included reductions in overall consumption and craving scores. Adverse events were the familiar ones: transient, generally mild to moderate gastrointestinal effects, more common in the semaglutide group.

The Mechanism Behind Ozempic Alcohol Cravings Reports

GLP-1 receptors are not confined to the pancreas and gut. They appear in brain regions that handle reward and motivation, which is the reason anyone thought to run these experiments.

The clearest mechanistic work comes from a 2023 study in JCI Insight. In mice, semaglutide dose-dependently reduced binge-like alcohol drinking; in rats, it reduced both binge-like and dependence-induced drinking. The researchers also recorded from neurons in the central amygdala — a hub for the negative emotional states that drive drinking in dependence — and found semaglutide increased inhibitory signaling in alcohol-naive animals, suggesting enhanced GABA release. In alcohol-dependent rats the effects were mixed, with no overall change. That is a partial answer, not a complete one, and the paper says so.

Primates got there first, in 2019. A study in Psychopharmacology gave GLP-1 agonists to alcohol-preferring vervet monkeys and reported that liraglutide and to a lesser extent exenatide significantly reduced alcohol consumption without signs of nausea and without changing water intake — the first demonstration of the effect in non-human primates.

The picture that emerges is a drug acting on the reward-value machinery rather than on willpower. If you want the underlying biology, our guides to why the brain craves alcohol and to alcohol and dopamine cover the circuits these drugs appear to be reaching into.

What the Pooled Evidence Says

A 2025 systematic review and meta-analysis in eClinicalMedicine gathered the human evidence on GLP-1 receptor agonists and alcohol. Across fourteen studies it reported a significant reduction in AUDIT scores (mean difference −7.81 points; 95% CI, −9.02 to −6.60) alongside lower drinking frequency, less consumption per drinking day, and reduced craving.

Two caveats belong next to that number rather than in a footnote. The heterogeneity statistic was I² = 87.5%, meaning the individual studies disagreed with each other a great deal — the pooled figure is an average across studies that were not measuring the same thing in the same way. And the authors' own conclusion is that large, dedicated randomized trials are still needed to confirm efficacy and define how these drugs should be used.

If you want to know where your own drinking sits on a screening measure like AUDIT, the alcohol addiction quiz runs it in a browser with nothing saved or sent.

Ozempic Is Not Approved for Alcohol Use Disorder

This needs saying plainly, because a lot of coverage skates past it.

The FDA prescribing information for Ozempic lists three indications: improving glycemic control in adults with type 2 diabetes, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease. Alcohol use disorder is not among them.

The medications that are approved for alcohol use disorder are the three NIAAA describes in its clinician resource: naltrexone, acamprosate, and disulfiram. They are non-addictive, prescribable in primary care, and — by NIAAA's own account — vastly underused, reaching only 1.6% of adults with past-year alcohol use disorder in a 2021 analysis. If a medication route interests you, that is the conversation with the best evidence behind it today. Our guide to medications that help you stop drinking walks through each one, and the Sinclair method covers the naltrexone-before-drinking protocol specifically.

Nothing here is prescribing advice, and nothing here should be used to start, stop, or change a medication. That is a conversation with your prescriber, who knows your history and your other drugs.

If You Are Already Taking a GLP-1 and You Drink

The label carries cautions that are worth knowing before you raise the subject with your clinician.

Pancreatitis. Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, and the label says to discontinue if it is suspected. Heavy alcohol use is itself a leading cause of pancreatitis, so this is a genuine overlap rather than a theoretical one.

Low blood sugar. The label warns that concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Alcohol pulls in the same direction: NIAAA's medicine-interaction fact sheet lists abnormally low blood sugar levels as a risk of combining alcohol with diabetes medications.

Gastrointestinal effects. GI reactions are the most common adverse events with these drugs, sometimes severe, and the label advises against use in severe gastroparesis. Alcohol irritates the same tissue.

Gallbladder disease. Also listed in the label's warnings, and worth mentioning if you have a history.

The framing to bring to the appointment is simple: "I drink about this much, here is my pattern, what should I know?" Prescribers can only account for the drinking they are told about.

What This Means If You Want to Drink Less Now

The trials are encouraging and they are not a plan. Both of them paired the drug with structure — weekly clinic visits in one, cognitive behavioral therapy in both arms of the other — and in the Lancet trial the placebo group still cut heavy drinking days by 26 percentage points. Structure did most of that work.

You can have the structure now, without a prescription. Logging what you actually drink, rather than what you remember drinking, is the step that changes the picture fastest; the true cost of drinking calculator makes the pattern concrete in money and hours. Zebra striping — alternating alcoholic and non-alcoholic drinks — lowers the peak of a given night without requiring you to decide anything about the next one. And when a craving arrives, the craving timer gives it somewhere to go for the ten or twenty minutes it usually takes to pass.

A drink you logged is data. It tells you something about a trigger, a time of day, a room. That is worth more than a clean-looking week you cannot learn anything from.

References

Hendershot CS, Bremmer MP, Paladino MB, et al. "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial." JAMA Psychiatry. 2025;82(4):395-405. https://pubmed.ncbi.nlm.nih.gov/39937469/
Klausen MK, Justesen SK, Pedersen JN, et al. "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial." The Lancet. 2026;407(10540):1687-1698. https://pubmed.ncbi.nlm.nih.gov/42070571/
Chuong V, Farokhnia M, Khom S, et al. "The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission." JCI Insight. 2023;8(12):e170671. https://insight.jci.org/articles/view/170671
Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. "Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys." Psychopharmacology. 2019;236(2):603-611. https://pubmed.ncbi.nlm.nih.gov/30382353/
Eshraghi R, Ghadimi DJ, Montazerinamin S, et al. "Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis." eClinicalMedicine. 2025;90:103645. https://pubmed.ncbi.nlm.nih.gov/41324012/
DailyMed, U.S. National Library of Medicine. "OZEMPIC (semaglutide) injection — FDA prescribing information." https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
National Institute on Alcohol Abuse and Alcoholism (NIAAA). "Recommend Evidence-Based Treatment: Know the Options." https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/recommend-evidence-based-treatment-know-options
National Institute on Alcohol Abuse and Alcoholism (NIAAA). "Harmful Interactions: Mixing Alcohol with Medicines." https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/harmful-interactions-mixing-alcohol-with-medicines

Frequently Asked Questions

Does Ozempic reduce alcohol cravings?

In two randomized trials, semaglutide reduced craving compared with placebo. The 2025 JAMA Psychiatry trial found lower weekly craving scores over nine weeks in 48 adults, and the 2026 Lancet trial found reduced craving alongside a 13.7 percentage-point advantage on heavy drinking days over 26 weeks. Both trials were small by drug-approval standards, and neither makes semaglutide an alcohol treatment.

Is semaglutide approved to treat alcohol use disorder?

No. The FDA label for Ozempic covers type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease in type 2 diabetes. Alcohol use disorder is not an approved indication for any GLP-1 drug. The three medications FDA-approved for alcohol use disorder are naltrexone, acamprosate, and disulfiram, and NIAAA notes they are badly underused.

Is it safe to drink alcohol while taking Ozempic?

That is a question for your prescriber, who knows your other medications. The label warns about acute pancreatitis, about hypoglycemia when combined with insulin or insulin secretagogues, about severe gastrointestinal reactions, and about gallbladder disease. Alcohol pushes in the same direction on several of those. Tell your prescriber your actual drinking pattern so they can advise on the real situation.

Why do people say Ozempic made them stop wanting wine?

The animal work points at reward circuitry rather than willpower. Semaglutide reduced binge-like drinking in mice and rats and altered inhibitory signaling in the central amygdala, and GLP-1 agonists cut alcohol intake in vervet monkeys. Human reports of alcohol simply losing its appeal are consistent with a drug that lowers reward value, which is also what the craving measures in both trials picked up.

Should I ask my doctor for a GLP-1 to help me drink less?

You can raise it, but go in knowing the evidence is early and the use would be off-label. The stronger opening question is about the approved options, since naltrexone and acamprosate have decades of trial data and reach only a small fraction of the people who could use them. Either way, this is a prescriber's decision, not a self-directed one.